Next Article in Journal
Shared Decision-Making in Chronic Patients with Polypharmacy: An Interventional Study for Assessing Medication Appropriateness
Next Article in Special Issue
Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer
Previous Article in Journal
Congenital Heart Defects in Monochorionic Twins: A Systematic Review and Meta-Analysis
Previous Article in Special Issue
Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
Open AccessReview

Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication

1
National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan
2
Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan
3
Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4
Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5
Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(6), 903; https://doi.org/10.3390/jcm8060903
Received: 30 May 2019 / Revised: 15 June 2019 / Accepted: 20 June 2019 / Published: 24 June 2019
The incidence of pancreatic cancer has considerably increased in the past decade. Pancreatic cancer has the worst prognosis among the cancers of the digestive tract because the pancreas is located in the posterior abdominal cavity, and most patients do not show clinical symptoms for early detection. Approximately 55% of all patients are diagnosed with pancreatic cancer only after the tumors metastasize. Therefore, identifying useful biomarkers for early diagnosis and screening high-risk groups are important to improve pancreatic cancer therapy. Recent emerging evidence has suggested that genetic and epigenetic alterations play a crucial role in the molecular aspects of pancreatic tumorigenesis. Here, we summarize recent progress in our understanding of the epigenetic alterations in pancreatic cancer and propose potential synthetic lethal strategies to target these genetic defects to treat this deadly disease. View Full-Text
Keywords: pancreatic cancer; epigenetic regulation; SWItch/Sucrose Non-Fermentable (SWI/SNF) complex; histone methylation; synthetic lethality pancreatic cancer; epigenetic regulation; SWItch/Sucrose Non-Fermentable (SWI/SNF) complex; histone methylation; synthetic lethality
Show Figures

Figure 1

MDPI and ACS Style

Hung, Y.-H.; Hsu, M.-C.; Chen, L.-T.; Hung, W.-C.; Pan, M.-R. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. J. Clin. Med. 2019, 8, 903. https://doi.org/10.3390/jcm8060903

AMA Style

Hung Y-H, Hsu M-C, Chen L-T, Hung W-C, Pan M-R. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Journal of Clinical Medicine. 2019; 8(6):903. https://doi.org/10.3390/jcm8060903

Chicago/Turabian Style

Hung, Yu-Hsuan; Hsu, Ming-Chuan; Chen, Li-Tzong; Hung, Wen-Chun; Pan, Mei-Ren. 2019. "Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication" J. Clin. Med. 8, no. 6: 903. https://doi.org/10.3390/jcm8060903

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop